Drug Development

Quoin Pharma's new drug name is a key step, but the path to the first-ever treatment for a rare skin disease reveals the complex interplay of innovation and finance.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

EpiVax's major lab expansion signals a pivotal shift in medicine, moving from flawed animal models to advanced tools that test drugs on human cells first.

The Oklahoma CDMO's move to integrate AI and 'high-touch' service isn't just a website refresh; it's a strategic play in a multi-billion dollar market.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

BioMendics secured a key FDA Fast Track designation for its EBS therapy, a strategic move that de-risks development and signals a new era for rare disease treatment.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

With a fresh $190M, Osanni Bio is pioneering a radical new model for drug discovery—building an ecosystem of specialized spinoffs to accelerate cures.

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

Veristat isn't just hiring; it's assembling a brain trust to conquer biotech's toughest frontiers. Here's the story behind its strategic talent grab.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

Nippon Shinyaku and Boston Children's Hospital deepen their pact, combining corporate might with research prowess to create new therapies for rare neurology.

A Boston biotech advances a first-in-class antibody into trials, aiming to halt the cellular engine of fibrosis that drives chronic kidney disease.